Rubedo has developed a novel class of senolytic targeted small molecules, including prodrugs, designed to be selectively activated in specific senescent cells to induce their clearance from tissues while protecting other cell types. These molecules involve multi-step activation, taking advantage of novel druggable targets and of characteristic senescent cell functions discovered through ALEMBIC™, enabling its proprietary medicinal chemistry. Those prodrugs solve three problems: 1) selectivity – activating only in the rare pathological cells but sparing the other healthy cells; 2) tolerability, protecting elderly individuals from side-effects caused by off-targets; 3) efficacy, generating potent active compounds acting on the selected targets.